Type I IFN receptor controls B cell expression of nucleic acid sensing toll-like receptors and autoantibody production in a murine model of lupus

IntroductionSystemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of high-titer IgG autoantibodies directed against nuclear autoantigens. Type I interferon (IFN-I) has been shown to play a pathogenic role in this disease. In the ongoing study, we characterized the role of the IFNAR2 chain of the IFN-I receptor in the targeting of nucleic acid-associated autoantigens and in B cell locution of the nucleic acid-sensing toll-like receptors (TLRs), TLR7 and TLR9, in the pristane example of lupus. Methods: Fierce type (WT) and IFNAR2-/- mice were treated with pristane and monitored for proteinuria on a monthly basis. Autoantibody production was determined by autoantigen microarrays and confirmed using enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation.

Markers of B lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort

IntroductionLittle is manifest approximately systemic B-cell activation in early rheumatoid arthritis (RA). We therefore evaluated the serum levels of markers of B-cell activation in patients included in the ESPOIR early arthritis cohort. Methods: In the ESPOIR early arthritis cohort (at least 2 swollen joints for exceeding than 6 weeks however less than 6 months), 710 patients were assessed at 1 year and either met the 1987 ACR criteria for RA (n= 578) or had undifferentiated arthritis (n= 132). Baseline serum samples of patients callow to corticosteroid and disease-modifying antirheumatic drug (DMARD) treatment were assessed for beta2-microglobulin, IgG, IgA, IgM, immunoglobulin free light chains (FLCs) of immunoglobulins, and B-cell activating cause of the tumor necrosis factor (TNF) family (BAFF).

Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies

IntroductionTo examine IL-17A in patients, adjacent anti-tumour necrosis factor-alpha (TNF-alpha) therapy and the causatum of IL-17A on matrix turnover and cartilage degradation. Methods: IL-17A term was examined by ELISA and immunohistology in the rheumatoid arthritis (RA) joints. RA entire synovial tissue explant (RA ST), influential synovial fibroblasts (RASFC), human cartilage and chondrocyte cultures were stimulated with IL-17A +/- TNF-alpha and Oncostatin M (OSM). Matrix metalloproteinase (MMP) and tissue inhibitor (TIMP-1) were assessed by ELISA and zymography. Cartilage proteoglycan proceeds was assessed histologically by Safranin-O staining. Clinical parameters, IL-17A, MMP/TIMP were assessed in patients pre/post biologic therapy.

Rheumatoid arthritis and smoking: putting the pieces together

Besides atherosclerosis and lung cancer, smoking is considered to play a major role in the pathogenesis of autoimmune diseases. It has long confessed that there is a connection between rheumatoid baggage consummate rheumatoid arthritis and cigarette smoking. Recently, an important gene-environment interplay has been revealed, i.e. carrying particular HLA-DRB1 alleles encoding the shared epitope and smoking set a significant risk for anti-citrullinated protein antibody positive rheumatoid arthritis. We summarise how smoking related alteration of the cytokine balance, the increased risk of infections (the opportunity of cross-reactivity) and modifications of autoantigens by citrullination may contribute to the augmentation of rheumatoid arthritis.

New data favouring that neurotrophins are of importance in arthritis

Neurotrophins are essential in inflammation. In an article in Arthritis Analysis & Therapy, Barthel and colloborators deed latest information on the lifetime of neurotrophin industry in the synovial tissue of arthritic joints. These findings, stable with other modern findings, stress that neurotrophins should be considered as determining factors in arthritis. That is reinforced by the news that they are also produced by articular chondrocytes and that receptors for these are contemporary in the synovial tissue and on chondrocytes. The import of neurotrophins in joints should be further studied, including examinations on the efficacy of interfering with their baggage in arthritis.

Immunization with an immunodominant self-peptide derived from glucose-6-phosphate isomerase induces arthritis in DBA 1 mice

IntroductionT helper (Th) lymphocytes are critically required for the pathogenesis of glucose-6-phosphate isomerase (G6PI)-induced arthritis, however neither the G6PI-epitopes recognized by arthritogenic T cells nor their pathogenic effector functions have been fully elucidated to date. We aimed at identifying arthritogenic G6PI-peptides. Methods: We used a lib of overlapping peptides spanning the comprehensive G6PI sequence to classify the epitopes recognized by G6PI-specific Th cells. Immunodominant peptides were then used to immunize mice. Arthritis development was evaluated clinically and histologically. The humoral and cellular resistant responses upon peptide-immunization were analyzed by ELISA and multiparameter flow cytometry, respectively.

Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients

IntroductionInterstitial lung disease (ILD) is a frequent manifestation of systemic sclerosis (SSc), and cytokines can contribute to the disease pathology. The objective of the happening recite was to distinguish particular changes in cytokine levels which may serve as disease markers and imaginable targets for therapy. Methods: Cytokines were measured by bioplex dialogue in 38 bronchoalveolar fluids (BALF) from 32 SSc patients (27 with alveolitis and 11 without alveolitis) and 26 control patients. In the case of SSc patients, cytokines were correlated with the respective bronchoalveolar lavage (BAL) cell differentiation, lung function, and thoracic HR-CT score.

Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 - more than just an anti-inflammatory effect? A cross sectional study

IntroductionThe metabolic syndrome (MetS) may contribute to the excess cardiovascular difficulty observed in rheumatoid arthritis (RA). The prevalence and associations of the MetS in RA remain uncertain: systemic inflammation and anti-rheumatic therapy may contribute. Methotrexate (MTX) application has recently been linked to a reduced presence of MetS, via an assumed generic anti-inflammatory mechanism. We aimed to: assess the prevalence of the MetS in RA; finger factors that associate with its presence; and assess their interplay with the likely influence of MTX. Methods: MetS prevalence was assessed cross-sectionally in 400 RA patients, using five MetS definitions (National Cholesterol Education Program 2004 and 2001, International Diabetes Federation, World Health Organization and European glance at Crowd for Insulin Resistance).

Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis

IntroductionRecent evidence suggests that uric acid (UA), regardless of crystal deposition, may play a govern pathogenic role in renal disease. We have shown that UA is an independent predictor of hypertension and cardiovascular disease (CVD), and that CVD risk factors associate with renal dysfunction, in patients with rheumatoid arthritis (RA). In this study we investigated if UA associates with renal dysfunction in patients with RA and whether such an firm is independent or mediated terminated other co-morbidities or risk factors for renal impairment. Methods: Renal servicing was assessed in 350 consecutive RA patients by estimated glomerular filtration standard (GFR) using the six- variable Altering of Diet in Renal Disease (MDRD) equation.

Gout. Novel therapies for treatment of gout and hyperuricemia

In the bygone unusual decades, gout has increased not alone in prevalence, but as well in clinical complexity, the latter accentuated in tool by a dearth of history advances in treatments for hyperuricemia and gouty arthritis. Fortunately, new trial reviewed here, much of it founded on elegant translational studies of the recent decade, highlights how gout can be more select managed with cost-effective, well-established therapies. In addition, the advent of both just out urate-lowering and anti-inflammatory drugs, also reviewed here, promises for improved management of recalcitrant gout, including in subjects with co-morbidities such as chronic kidney disease.